GPT Healthcare profit and loss

Latest FY26
Revenue
₹473cr+16.1% on FY25
EBITDA
₹84.2cr+1.0% on FY25
Net profit
₹42.2cr−15.4% on FY25
EPS
₹5.15−15.3% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
492473407400
6.46.08.55.3
498478416405
Expenses
93.389.878.883.0
87.284.473.068.9
8.88.23.57.1
27.827.119.018.0
220214172160
437424346337
91.084.283.487.8
63.257.164.369.9
Profit
60.954.869.368.0
60.954.869.368.0
15.312.612.111.9
−1.70.07.38.4
13.612.619.420.3
47.342.249.947.8
47.342.249.947.8
−0.1−0.1−0.00.0
47.142.149.947.8
Per share
₹5.76₹5.15₹6.08₹5.96
₹5.76₹5.15₹6.08₹5.96
Other comprehensive income — detail
−0.1−0.1−0.0—
—−0.2−0.10.0
—−0.1−0.0—
———0.0
−0.00.00.0—
Per share — as-filed variants
₹5.76₹5.15₹6.08₹5.96
₹5.76₹5.15₹6.08₹5.96
Derived — gross profit (revenue − materials − purchases − Δ inventories)
398383328317
81.0%81.0%80.6%79.3%
Adjusted (ex-exceptional items) — derived
60.954.869.368.0
47.342.249.947.8
₹5.76₹5.15₹6.08₹5.96
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GPTHEALTH₹136.89

GPT Healthcare Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersGKSLSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,123 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations400.2407.1472.5491.6
Other Income5.38.56.06.4
Total Income405.5415.6478.5498.1
Expenses
+ Cost of Materials Consumed83.078.889.893.3
+ Employee Benefit Expense68.973.084.487.2
+ Finance Costs7.13.58.28.8
+ Depreciation & Amortisation18.019.027.127.8
+ Other Expenses160.5171.9214.2220.2
Total Expenses337.4346.2423.7437.2
EBITDA87.883.484.291.0
EBIT69.964.357.163.2
Profit
PBT before Exceptional Items68.069.354.860.9
Pretax Income68.069.354.860.9
+ Current Tax11.912.112.615.3
+ Deferred Tax8.47.30.0-1.7
Tax Expense20.319.412.613.6
Net Income47.849.942.247.3
+ Net Income — Continuing Ops47.849.942.247.3
+ Other Comprehensive Income0.0-0.0-0.1-0.1
Total Comprehensive Income47.849.942.147.1
Per Share
Basic EPS5.966.085.155.76
Diluted EPS5.966.085.155.76
Other Comprehensive Income — detail
+ Other Comprehensive Income—-0.0-0.1-0.1
+ Items NOT to be Reclassified to P&L0.0-0.1-0.2—
+ Tax on Items NOT to be Reclassified—-0.0-0.1—
+ Tax on Items NOT to be Reclassified — alt tag0.0———
+ Tax on Items to be Reclassified—0.00.0-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations5.966.085.155.76
Diluted EPS — Continuing Operations5.966.085.155.76
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit317.2328.3382.8398.4
Gross Margin %79.2780.6481.0081.03
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)68.069.354.860.9
Net Income Adj (tax-effected)47.849.942.247.3
EPS Adj5.966.085.155.76
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital82.182.182.182.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.